Neurocrine Biosciences (NBIX) News Today $120.69 +4.58 (+3.94%) Closing price 04:00 PM EasternExtended Trading$120.78 +0.09 (+0.08%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase ProgramFebruary 21 at 8:00 AM | prnewswire.comLeerink Partnrs Issues Optimistic Outlook for NBIX EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Leerink Partnrs lifted their Q1 2025 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research note issued to investors on Monday, February 17th. Leerink Partnrs analyst M. Goodman now forecasts that the companFebruary 21 at 6:14 AM | marketbeat.comLeerink Partnrs Issues Negative Estimate for NBIX EarningsFebruary 21 at 2:25 AM | americanbankingnews.comLeerink Partnrs Has Pessimistic View of NBIX Q3 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Neurocrine Biosciences in a research report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now expects that the company will earnFebruary 20 at 7:02 AM | marketbeat.comIeq Capital LLC Buys 45,424 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Ieq Capital LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 557,904 shares of the company's stock after acquiring an aFebruary 20 at 5:33 AM | marketbeat.comDSM Capital Partners LLC Has $127.30 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)DSM Capital Partners LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 932,595 shares of the company's stock aFebruary 19 at 6:36 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vontobel Holding Ltd.Vontobel Holding Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,442 shares of the company's stock after sellFebruary 19 at 3:47 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Rice Hall James & Associates LLCRice Hall James & Associates LLC decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 110,632 shares of the company's stock aFebruary 18 at 6:49 AM | marketbeat.comStockNews.com Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to BuyStockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Tuesday.February 18 at 1:16 AM | marketbeat.comAlphaCentric Advisors LLC Sells 18,816 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)AlphaCentric Advisors LLC cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 83.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,684 shares of the company's stock after selling 18,816 shares duringFebruary 17, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by New York State Teachers Retirement SystemNew York State Teachers Retirement System lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,536 shares of the coFebruary 17, 2025 | marketbeat.comVan ECK Associates Corp Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Van ECK Associates Corp increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 11.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 93,406 shares of the company's stock after acquiring an additionalFebruary 16, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 1,551 SharesNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Julie Cooke sold 1,551 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.78, for a total transaction of $181,125.78. Following the completion of the sale, the insider now directly owns 19,544 shares in the company, valued at $2,282,348.32. This trade represents a 7.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.February 15, 2025 | marketbeat.comKevin Charles Gorman Sells 5,844 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Kevin Charles Gorman sold 5,844 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.69, for a total value of $681,936.36. Following the transaction, the director now directly owns 521,618 shares in the company, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.February 15, 2025 | marketbeat.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Sells 2,558 Shares of StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) CFO Matt Abernethy sold 2,558 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $116.86, for a total value of $298,927.88. Following the sale, the chief financial officer now directly owns 34,775 shares in the company, valued at $4,063,806.50. The trade was a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.February 15, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest UpdateNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 2,400,000 shares, a drop of 25.0% from the January 15th total of 3,200,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is currently 2.1 days.February 15, 2025 | marketbeat.comNeurocrine Biosciences' chief corporate affairs officer sells shares worth $208,387February 15, 2025 | msn.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $181,125.78 in StockFebruary 15, 2025 | insidertrades.comNeurocrine Biosciences chief legal officer sells $254,991 in stockFebruary 14, 2025 | msn.comNeurocrine Biosciences chief commercial officer sells $251,426 in stockFebruary 14, 2025 | msn.comNeurocrine Biosciences director sells $681,913 in stockFebruary 14, 2025 | investing.comNeurocrine Biosciences CHRO sells shares worth $181,129February 14, 2025 | investing.comNeurocrine Biosciences chief scientific officer sells $336,238 in stockFebruary 14, 2025 | investing.comAllspring Global Investments Holdings LLC Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Allspring Global Investments Holdings LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 30.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 480,565 shares of the companyFebruary 14, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Earns Hold Rating from Analysts at Deutsche Bank AktiengesellschaftFebruary 14, 2025 | americanbankingnews.comAnalysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $169.20February 14, 2025 | americanbankingnews.comStanley Laman Group Ltd. Purchases 4,627 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Stanley Laman Group Ltd. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,158February 13, 2025 | marketbeat.comFiera Capital Corp Sells 17,692 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Fiera Capital Corp lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 499,109 shares of the company's stock after selling 17,692 sFebruary 13, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 700 SharesFebruary 13, 2025 | insidertrades.comSavant Capital LLC Invests $2.26 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Savant Capital LLC purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 16,543 shares of the company's stock, valued at approFebruary 13, 2025 | marketbeat.comNeurocrine Biosciences CFO Matt Abernethy sells $115,908 in stockFebruary 13, 2025 | msn.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Julie Cooke Sells 700 SharesNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Julie Cooke sold 700 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total transaction of $82,796.00. Following the completion of the sale, the insider now owns 18,831 shares of the company's stock, valued at approximately $2,227,330.68. This represents a 3.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.February 12, 2025 | marketbeat.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $116,022.20 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) CEO Kyle Gano sold 980 shares of the business's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $118.39, for a total value of $116,022.20. Following the completion of the transaction, the chief executive officer now directly owns 137,658 shares in the company, valued at approximately $16,297,330.62. This represents a 0.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.February 12, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $269,173.38 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Kevin Charles Gorman sold 2,274 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $118.37, for a total transaction of $269,173.38. Following the transaction, the director now directly owns 519,074 shares in the company, valued at $61,442,789.38. This represents a 0.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.February 12, 2025 | marketbeat.comNeurocrine Biosciences chief legal officer sells $107,727 in stockFebruary 12, 2025 | investing.comNeurocrine Biosciences chief medical officer sells $115,852 in stockFebruary 12, 2025 | investing.comNeurocrine Biosciences director sells shares worth $269,167February 12, 2025 | investing.comNeurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY LaunchFebruary 12, 2025 | tipranks.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 4.9% on Analyst DowngradeFebruary 12, 2025 | americanbankingnews.comNeurocrine initiated with a Hold at Deutsche BankFebruary 11, 2025 | markets.businessinsider.comDeutsche Bank Aktiengesellschaft Initiates Coverage on Neurocrine Biosciences (NASDAQ:NBIX)Deutsche Bank Aktiengesellschaft started coverage on Neurocrine Biosciences in a research note on Tuesday. They issued a "hold" rating and a $138.00 price objective on the stock.February 11, 2025 | marketbeat.comSG Americas Securities LLC Sells 7,022 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)SG Americas Securities LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 86.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,062 shares of the company's stock after selling 7,022 shaFebruary 11, 2025 | marketbeat.comDecoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT InsightFebruary 11, 2025 | gurufocus.comNeurocrine price target lowered to $163 from $165 at GuggenheimFebruary 10, 2025 | markets.businessinsider.comWhy Neurocrine Biosciences Inc. (NBIX) Crashed Last WeekFebruary 10, 2025 | msn.comNeurocrine Biosciences (NASDAQ:NBIX) Upgraded by StockNews.com to Strong-Buy RatingStockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Monday.February 10, 2025 | marketbeat.comWhy Neurocrine Biosciences Stock Sank TodayFebruary 10, 2025 | fool.comNeurocrine Biosciences (NASDAQ:NBIX) Trading Down 4.9% After Analyst DowngradeNeurocrine Biosciences (NASDAQ:NBIX) Shares Down 4.9% After Analyst DowngradeFebruary 10, 2025 | marketbeat.comGuggenheim Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $163.00Guggenheim dropped their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a report on Monday.February 10, 2025 | marketbeat.comNeurocrine (NBIX) Gets a Buy from Evercore ISIFebruary 10, 2025 | markets.businessinsider.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.560.60▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼3213▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today Incyte News Today BioMarin Pharmaceutical News Today Exelixis News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBIX Stock Alerts